A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)

Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). Intismeran autogene is designed to help a person's immune system attack their specific cancer.
The goal of this study is to learn if people who receive intismeran autogene with pembrolizumab and chemotherapy live longer overall and without the cancer growing or spreading compared to people who receive placebo with pembrolizumab and chemotherapy. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of the study treatment.

开始日期2025-12-12

申办/合作机构

Merck Sharp & Dohme LLC

[+1]

NCT06833073

/ Recruiting临床2期

A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)

Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment. HR NMIBC can also include carcinoma in situ (CIS). CIS is bladder cancer that appears flat and is only in the inner layer (surface) of the bladder. CIS is not raised and is not growing toward the center of the bladder.
The standard treatment for HR NMIBC is a procedure to remove the tumor called transurethral resection of the bladder tumor (TURBT) followed by Bacillus Calmette-Guerin (BCG). Standard treatment is something that is considered the first line of treatment for a condition. BCG is an immunotherapy, which is a treatment that helps the immune system fight cancer. However, BCG may not work to treat HR NMIBC in some people. Researchers want to learn if adding intismeran autogene, the study treatment, to standard treatment can help treat HR NMIBC. Intismeran autogene is designed to help a person's immune system attack their specific cancer.
The goal of this study are to learn if people who receive V940 with BCG live longer and without the cancer growing, spreading, or coming back compared to people who receive BCG alone.

开始日期2025-03-11

申办/合作机构

Merck Sharp & Dohme LLC

[+1]

NCT06295809

/ Terminated临床2/3期

A Phase 2/3, Adaptive, Randomized, Open-label, Clinical Study to Evaluate Neoadjuvant and Adjuvant Intismeran Autogene (mRNA-4157) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care, and Pembrolizumab Monotherapy in Participants With Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (INTerpath-007)

This is a two-part (Phase 2/Phase 3) study of intismeran autogene, an individualized neoantigen therapy (INT), plus pembrolizumab in participants with locally resectable advanced cutaneous squamous cell carcinoma (LA cSCC). Phase 2 has three arms intismeran autogene plus pembrolizumab given as neoadjuvant and adjuvant treatment with standard of care (SOC), standard of care (surgical resection with/without adjuvant radiation therapy (RT) only at investigator's discretion) and pembrolizumab monotherapy given as neoadjuvant and adjuvant treatment with SOC. This phase will assess the safety and efficacy of intismeran autogene in combination with pembrolizumab as neoadjuvant and adjuvant therapy in participants with resectable LA cSCC as compared to standard of care SOC only. The primary hypothesis is that intismeran autogene plus pembrolizumab with SOC is superior to SOC only with respect to event free survival (EFS) as assessed by the investigator. Phase 3 expansion will be determined by prespecified Go-No-Go decision in which 412 additional participants will be randomized to intismeran autogene plus pembrolizumab with SOC and SOC only, without changing the inclusion/exclusion criteria for the additional enrollment or study endpoints.
As of Amendment 04, enrollment was stopped and there will be no Phase 3 expansion.

开始日期2024-04-18

申办/合作机构

Merck Sharp & Dohme LLC

[+1]

100 项与 Intismeran Autogene 相关的临床结果

登录后查看更多信息

100 项与 Intismeran Autogene 相关的转化医学

登录后查看更多信息

100 项与 Intismeran Autogene 相关的专利（医药）

登录后查看更多信息

项与 Intismeran Autogene 相关的文献（医药）

2026-10-01·Journal of Advanced Research

Biomimetic and personalized nanovaccines in cancer immunotherapy: Design innovations, translational challenges, and future directions

Review

作者: Minev, Boris ; Ma, Wenxue ; Yang, Haitao ; Xu, Suling

Personalized nanovaccines represent advancing frontier in cancer immunotherapy by integrating patient-specific tumor antigens with biomimetic delivery systems to enhance immune activation, targeting precision and clinical efficacy. Biomimetic platforms including exosome-, red blood cell (RBC)-, and immune cell membrane-coated nanoparticles, as well as artificial antigen-presenting cell (aAPC) systems, recreate native biological interfaces to improve antigen presentation, macrophage polarization, and adaptive immune priming. Despite significant progress, major translational challenges remain, including incomplete mechanistic understanding, regulatory complexity, and manufacturing scalability. This review synthesizes recent advances in biomimetic and personalized nanovaccine design, highlighting clinical progress in lipid nanoparticle (LNP)-based vaccines such as BNT111 and mRNA-4157, emerging innate immune adjuvants including Toll-like receptor (TLR) and stimulator of interferon genes (STING) agonists, and rational combination strategies with immune checkpoint blockade. Key safety and quality consideration including immunotoxicity, off-target immune activation, and batch heterogeneity are critically evaluated alongside emerging engineering solutions. Finally, future directions integrating AI-guided neoantigen prediction, modular microfluidic manufacturing, and multi-omic biomarker frameworks are discussed to accelerate next generation cancer nanovaccine translation.

2026-09-01·Annals of thoracic surgery short reports

Study Designs for INTerpath-002 and INTerpath-009 of Adjuvant Intismeran Autogene Plus Pembrolizumab for Non-Small Cell Lung Cancer

Article

作者: Wang, Zheng ; Bestvina, Christine M ; Shariati, Nazly ; Lee, Jay M ; Spicer, Jonathan D ; Banerjee, Joydeep K ; Cascone, Tina ; Marron, Thomas U ; Keller, Steven M ; Peters, Solange ; Chaft, Jamie E ; Gainor, Justin F ; Deng, Xuan ; Ojalvo, Laureen S ; Khattak, Muhammad A

Background:

Neoantigens are immunogenic molecules arising from patient-specific tumor mutations. Intismeran autogene (intismeran; formerly V940, mRNA-4157), an mRNA-based individualized neoantigen therapy (INT) encoding ≤34 neoantigens unique to each patient's tumor, is designed to promote an antitumor immune response. In early-phase studies, adjuvant intismeran plus pembrolizumab showed antitumor activity with solid tumors. Standard-of-care therapy for non-small cell lung cancer (NSCLC) tumors ≥4 cm includes platinum-based chemotherapy and pembrolizumab given after (adjuvant) or both before and after (perioperative) surgical resection. We describe study designs for the INTerpath-002 and INTerpath-009 studies evaluating the addition of intismeran to adjuvant pembrolizumab-based therapy in stage II-IIIB (N2) NSCLC.

Methods:

INTerpath-002 and INTerpath-009 are randomized, double-blind, phase 3 trials. Eligible participants for INTerpath-002 have completely resected, margin-negative, stage II-IIIB (N2) NSCLC (American Joint Committee on Cancer staging manual, eighth edition) and have received 1 to 4 cycles of adjuvant platinum-based chemotherapy. Eligible participants for INTerpath-009 have resectable stage II-IIIB (N2) NSCLC and have received ≤4 cycles of neoadjuvant pembrolizumab plus chemotherapy every 3 weeks. Participants with tumors that do not achieve a pathologic complete response, per pathologic examination of the resected tumor specimen, and have R0-R1 resection are eligible for randomized treatment. In both studies, participants are randomized 1:1 to receive pembrolizumab intravenously every 6 weeks plus either intismeran intramuscularly every 3 weeks or placebo. The primary endpoint in both studies is disease-free survival per investigator.

Results:

Recruitment is ongoing for both studies.

Conclusions:

Results from these studies will provide insight into the potential role of INT in NSCLC.

2026-05-01·Translational Oncology

Personalized and HPV cancer vaccines in head and neck squamous cell carcinoma: from concept to clinical implementation

Review

作者: Le Tourneau, Christophe ; Filippini, Daria Maria

Head and neck squamous cell carcinoma (HNSCC) remains a challenging malignancy, with limited survival improvements despite recent advances with immune checkpoint inhibitors (ICIs). Within this context, personalized neoantigen vaccines and HPV-targeted therapeutic vaccines are emerging as innovative strategies aimed at enhancing antitumor immunity. Personalized vaccines exploit tumor-specific mutational landscape to generate highly individualized T cell responses, demonstrating favorable safety profiles and durable immunogenicity in early-phase trials. Compounds such as TG4050, mRNA-4157, and PGV001 have shown early, hypothesis-generating signals of activity (from small early-phase studies), particularly in the adjuvant setting. HPV-targeted vaccines, including PDS0101, BNT113, and CUE-101, are being explored in HPV-positive HNSCC, mainly in combination with ICIs. While some early clinical activity has been observed, these signals should be interpreted cautiously given limited sample sizes, heterogeneous populations, and exploratory endpoints in many studies, and randomized trials such as ISA101b have failed to show survival benefits over ICIs alone. Overall, therapeutic vaccination appears safe and immunologically active, yet its efficacy is constrained by the immunosuppressive tumor microenvironment. The greatest clinical potential of therapeutic vaccination may lie in earlier disease stages, where the tumor burden is lower and immune modulation more feasible. Further clinical and translational research is needed to define the optimal integration of vaccine-based therapies into multimodal treatment paradigms for HNSCC.

1,999

项与 Intismeran Autogene 相关的新闻（医药）

2026-10-09

·非著名猎头顾问

重金揽才，mRNA赛道迎来一次重量级人才引进

就在今天，港股创新药企云顶新耀（1952.HK）抛出了一则在行业内关注度很高的人事官宣。 Lakshmi Srinivasan博士正式出任高级副总裁、转化医学负责人； Brandon Coder博士担任转化科学与早期研究副总裁; 两位重磅人才，全部来自全球mRNA领域的标杆企业莫德纳Moderna 。在生物医药圈子里面，从莫德纳出走的资深研发人员，一直都是各家企业争相去争取的稀缺资源。原因很简单：这家企业不仅靠着mRNA新冠疫苗一战成名，更是在全球mRNA肿瘤疫苗的赛道中，跑出了目前行业唯一一条III期临床取得阳性结果的产品——mRNA‑4157。而本次入职云顶新耀的两位科学家，恰恰就是深度参与过这条明星管线研发与转化工作的核心人员。先简单看一看两位博士的履历底色。Lakshmi Srinivasan博士拥有长达20年的肿瘤免疫领域研发经验，工作覆盖了靶点发现、转化研究再到早期临床的全链条。在莫德纳任职期间，她担任执行总监，主导肿瘤疫苗项目的转化医学策略制定，非常熟悉美国临床申报和试验推进的整套逻辑。另一位Brandon Coder博士，则长期扎根于mRNA的早期科学探索，主攻候选分子的筛选、临床前概念验证，是衔接实验室技术走向临床试验的关键角色。加入云顶新耀之后，他们的核心任务非常清晰：主攻mRNA肿瘤疫苗在美国市场的临床开发工作，并且和国内的研发团队形成联动，加速企业整个mRNA技术平台的全球化布局。换句话说，不是简单坐在美国办公室做基础实验，而是要去打通从美国IND申报、临床机构对接、试验运营到数据回传国内研发端的整条链路。可能很多人会好奇，为什么一家国内创新药企，要不惜成本去引进海外的科学家，专门负责美国区域的临床？这里其实藏着当下国内mRNA企业发展的一道坎。不少本土公司可以在国内把技术平台搭建起来，做出候选药物，但是一旦想要迈出去，在美国做临床开发，就会碰到各种各样无形的门槛。不仅仅是法规条文的差异，更多在于对当地临床资源、研究者沟通、临床方案设计、监管沟通语言体系的理解。如果团队缺乏在美国本土操盘项目的实战经验，很容易走弯路，拉长研发周期，消耗大量资金。云顶新耀其实很早就在mRNA赛道埋下了棋子。目前这家公司已经打造了一套自研的AI+mRNA技术底座，建成了从抗原设计、序列优化、LNP递送、工艺开发到规模化生产的完整链条。管线当中，现货型mRNA肿瘤疫苗EVM14已经拿到了中美两地的IND批件；个性化新抗原疫苗EVM16也已经完成了初步的人体试验，并且在AACR大会公布了早期积极信号；多条后续产品也在稳步向前推进。但是，想要真正把管线在美国跑起来，光有钱和分子还不够，必须要有懂美国游戏规则、并且经历过实战的带头人去牵头。这大概就是这次大手笔引才背后的底层逻辑。找曾经在莫德纳操盘过同类项目的人，本质上也是在降低出海试错的成本。当然，人才引进只是一个新的起点。mRNA赛道，从来不缺雄心，缺的是漫长研发周期里面持续稳定的执行力。两位海外专家到来之后，还需要和国内研发团队做好节奏磨合，把两边的技术思路打通，平衡中美两地不同的临床推进节奏。跨国团队协同，本身也是一道不小的考题。放眼整个国内生物医药行业，出海已经不再是一个可选项，慢慢变成了很多头部创新企业的必答题。而出海的模式，也正在悄然发生变化。早些年，不少企业的出海是把产品授权出去，赚取首付款和里程碑；如今越来越多的公司，开始主动在美国建立研发与临床的触角，招募本土顶尖人才，直接去做全球同步开发。人才争夺战，自然而然就成为了竞争当中非常重要的一环。 mRNA这条赛道，竞争已经日趋白热化。每一家入局者，都在想尽办法补齐自己的短板。这次云顶新耀的人才引进，给行业提供了一个观察样本：当一家本土企业准备好了自研的技术管线之后，下一步如何依靠国际化的人才，去叩开全球市场的大门。至于后续能不能交出令人惊喜的成绩单，依旧需要交给漫长的时间去验证。免责声明: 本文基于企业公开公告信息整理，仅为医药产业人事资讯解读，不构成任何投资建议。企业经营战略、管线进展及人事后续工作安排，以企业官方披露信息为准。

2026-10-09

·湖商网

两位前莫德纳肿瘤疫苗资深科学家加盟云顶新耀mRNA全球临床开发提速

来源 Everest Medicines Limited 两位前莫德纳肿瘤疫苗资深科学家加盟云顶新耀mRNA全球临床开发提速香港, 2026年10月9日 - (亚太商讯) - 云顶新耀（1952.HK）宣布任命Lakshmi Srinivasan博士担任高级副总裁、转化医学负责人，Brandon Coder博士担任转化科学与早期研究副总裁。两位新任高管均拥有深厚的行业经验和专业背景，此前曾在莫德纳等全球领先的生物制药企业负责肿瘤疫苗研发，具备从早期发现到临床转化及临床开发的完整实战经验。此次重磅引才，是云顶新耀加速推进mRNA全球战略的关键举措，将进一步强化云顶新耀mRNA技术平台的全球研发能力与国际合作布局。两位科学家将在云顶新耀管理层的领导下，重点推动云顶新耀mRNA技术平台在美国的临床开发及相关业务布局，并与中国研发团队密切协作，进一步赋能mRNA技术平台的进化。值得关注的是，两位科学家此前所任职的莫德纳，是全球mRNA肿瘤治疗领域最具代表性的企业之一。2026年8月，莫德纳与默沙东宣布，mRNA-4157/V940联合Keytruda在III期INTerpath-001研究中达到无复发生存期主要终点及无远处转移生存期关键次要终点，成为首个在III期临床研究中取得阳性结果的mRNA肿瘤疗法及个体化新抗原疗法。此前，IIb期KEYNOTE-942研究五年随访结果也显示，该联合方案相较于Keytruda单药可降低患者复发或风险及远处转移或死风险。目前，相关研发已拓展至多个癌种。两位科学家此前在莫德纳参与相关肿瘤疫苗项目，积累了从早期研究到临床开发的实践经验，为云顶新耀进一步推进自主mRNA平台的全球临床开发提供了重要专业支撑。云顶新耀董事会主席吴以芳表示：“我们非常高兴Srinivasan博士和Coder博士加入云顶新耀。两位资深科学家在肿瘤疫苗研发、转化医学及临床开发领域拥有深厚经验，将进一步强化公司的全球mRNA研发能力，助力推进自主mRNA技术平台及相关产品管线的全球临床开发。此次任命体现了云顶新耀持续汇聚全球顶尖人才、推进全球mRNA战略的承诺。” 据了解，Srinivasan博士拥有20年肿瘤免疫领域研发经验，作为资深免疫学家，她长期致力于推动创新肿瘤免疫疗法从早期发现研究走向临床开发，在肿瘤疫苗、mRNA-LNP（脂质纳米颗粒）技术、T细胞疗法及转化医学开发等领域拥有丰富经验，研发经验覆盖从临床前研究到临床概念验证的多个阶段。加入云顶新耀前，Srinivasan博士于2023年至2025年就职于莫德纳（Moderna Therapeutics），曾任执行总监、肿瘤转化医学负责人；此前她曾任Repertoire Immune Medicines副总裁、临床前科学与转化医学负责人，Neon Therapeutics（后并入BioNTech）转化科学高级总监及赛诺菲（Sanofi）肿瘤药物发现负责人。Srinivasan博士长期从事个性化新抗原疫苗临床转化研究，并在该领域发表多篇高影响力学术论文。她作为通讯作者参与了NEO-PV-01的Ib期临床研究，相关研究成果分别发表于《Cell》（2020年）和《Cancer Cell》（2022年）。此外，她也作为共同作者参与了莫德纳 intismeran autogene（mRNA-4157/V940）的多篇代表性论文，包括发表于《Cancer Discovery》（2024年）的I期KEYNOTE-603研究中mRNA-4157/V940单药及联合帕博利珠单抗治疗所诱导的T细胞应答；以及发表于《JCO Oncology Advances》（2026年）的mRNA-4157/V940联合帕博利珠单抗治疗切除后黑色素瘤的随机IIb期 KEYNOTE-942研究3年随访结果。 Coder博士拥有超过11年的生物医药行业研发经验，长期致力于推动T细胞免疫疗法从早期发现研究走向IND申报及早期临床概念验证。他在肿瘤疫苗、mRNA/LNP平台技术及in vivo CAR疗法领域拥有丰富经验。加入云顶新耀前，他于2019年至2025年任职莫德纳，曾任肿瘤疫苗研究及早期临床转化负责人、副科学总监，并担任mRNA-4157/V940的研究、早期转化及全球药理学负责人——该产品于2026年8月公布III期INTerpath-001研究阳性结果，成为全球首个在III期临床中取得成功的个性化新抗原疗法及mRNA肿瘤疗法。他还是莫德纳共享抗原肿瘤疫苗mRNA-4359的共同发明人及研究负责人，并是共享抗原疫苗策略及设计框架的共同发明人，相关策略应用于莫德纳共享抗原肿瘤疫苗产品组合。此外，他作为共同发明人、研究负责人或核心贡献者参与了9项IND申报，也是《Cancer Discovery》（2024年）KEYNOTE-603研究论文的共同作者。加入莫德纳前，他曾任Advaxis Immunotherapies肿瘤免疫研发副总监及肿瘤疫苗研究负责人。基于自主知识产权的AI+mRNA平台，云顶新耀正多路径推进mRNA肿瘤治疗性疫苗和自体生成CAR-T平台，治疗肿瘤及自身免疫疾病。目前，个性化肿瘤治疗性疫苗EVM16完成首次人体临床数据读出，显示出良好的安全性、耐受性、显著的免疫原性及积极的初步疗效信号，部分数据已于2026年美国癌症研究协会（AACR）年会上公布。EVM16计划于2026年第四季度启动IIT（研究者发起的临床试验）Ib期临床研究，并在Ia研究基础上，开展新的适应症扩展队列，进行有效性探索，并计划于2027 H1递交美国食品药品监督管理局（FDA）新药临床试验（IND）申请；通用现货型肿瘤相关抗原（TAA）疫苗EVM14，继2025年相继获得美国FDA及中国国家药品监督管理局“双重IND”批准后，公司将于2027年第一季度完成临床I期单药剂量递增；自体生成CAR-T疗法EVM18已启动针对自身免疫疾病的IIT研究，同时公司正稳步推进其全球IND申报工作；免疫调节肿瘤疫苗EVM15于2025年取得临床前概念验证，确定临床候选分子，公司计划于2026年推进EVM15的新药临床试验申请准备工作。两位肿瘤疫苗资深科学家的加盟，是云顶新耀加速mRNA全球战略的关键一步，也体现了公司全球研发资源与人才实力的快速提升。随着国际化团队持续壮大、全球资源加速汇聚，云顶新耀将进一步巩固自主AI+mRNA平台的技术优势，推动mRNA肿瘤疫苗及自体生成CAR-T管线在全球范围内梯次落地，持续深化全球化布局，为全球患者带来更多创新治疗选择。

2026-10-09

·东方财富网

云顶新耀引入两位前莫德纳核心科学家

10月9日，港股创新药企云顶新耀宣布任命Lakshmi Srinivasan博士担任高级副总裁、转化医学负责人，Brandon Coder博士担任转化科学与早期研究副总裁。公司表示，两位新任高管将重点推动mRNA技术平台在美国的临床开发及相关业务布局，并与中国研发团队密切协作，进一步赋能mRNA技术平台的迭代升级。　　据了解，两位科学家此前均任职于莫德纳，曾深度参与个性化新抗原mRNA疗法V940/mRNA-4157的核心研发与临床转化。该疗法是全球首个在III期临床研究中取得阳性结果的个性化新抗原疗法及mRNA肿瘤疗法。此次引进资深科学家，释放出云顶新耀持续强化mRNA平台全球临床开发能力的战略信号。　　对此，云顶新耀董事会主席吴以芳表示，此次任命体现了云顶新耀持续汇聚全球顶尖人才、推进全球mRNA战略的承诺。“两位资深科学家在肿瘤疫苗研发、转化医学及临床开发领域拥有深厚经验，将进一步强化公司的全球mRNA研发能力，助力推进自主mRNA技术平台及相关产品管线的全球临床开发。”　　资料显示，Lakshmi Srinivasan博士拥有20年肿瘤免疫领域研发经验。作为资深免疫学家，她长期致力于推动创新肿瘤免疫疗法从早期发现走向临床开发，在肿瘤疫苗、mRNA-LNP（脂质纳米颗粒）技术、T细胞疗法及转化医学开发等领域拥有丰富经验，研发覆盖从临床前研究到临床概念验证的多个阶段。　　Brandon Coder博士拥有超过11年的生物医药行业研发经验，长期致力于推动T细胞免疫疗法从早期发现走向IND申报及早期临床概念验证。他曾作为核心研发成员参与9项IND申报，覆盖个性化新抗原、共享抗原、免疫调节型mRNA及in vivo CAR（体内CAR）等多个肿瘤免疫治疗项目，研发经验贯穿候选药物发现、IND申报、早期临床转化及后续开发阶段。（文章来源：中国证券报·中证网）

100 项与 Intismeran Autogene 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非小细胞肺癌Ⅰ期	临床3期	美国	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	日本	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	澳大利亚	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	巴西	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	加拿大	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	智利	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	哥伦比亚	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	法国	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	德国	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	希腊	Merck Sharp & Dohme LLC	2026-05-04

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2026	临床1/2期	黑色素瘤辅助	7	Intismeran autogene + pembrolizumab	醖夢積鹽衊糧範醖願鑰(鬱淵蓋淵製顧襯壓選醖) = 鹹鏇淵鑰網獵餘醖餘廠鹽鹹餘壓醖製觸獵艱膚 (範衊獵製範糧獵簾壓願 ) 更多	积极	2026-05-29
NCT03897881 (KEYNOTE-942, ASCO2026)	临床2期	黑色素瘤	157	intismeran + pembro	壓餘鬱網鹹獵願構遞鬱(範鬱網窪餘築範構製醖) = 襯鹹廠糧獵觸範積鬱積糧憲網壓繭簾鏇齋憲衊 (餘鹽壓觸鑰憲獵獵構鹹, 56.3 ~ 78.3) 更多	积极	2026-05-29
				pembro	壓餘鬱網鹹獵願構遞鬱(範鬱網窪餘築範構製醖) = 構廠艱壓淵遞艱繭膚艱糧憲網壓繭簾鏇齋憲衊 (餘鹽壓觸鑰憲獵獵構鹹, 33.3 ~ 63.0) 更多
NCT07221474 (INTerpath-013, ASCO2026)	临床2期	鳞状非小细胞肺癌一线	180	Pembrolizumab + carboplatin + (paclitaxel or nab-paclitaxel) + Intismeran autogene	淵淵範淵網廠鹹鹹願遞(選鹹選鬱築齋醖遞簾鹹) = 獵鑰觸夢蓋醖艱鬱觸顧選鑰鏇醖醖窪鹹願壓蓋 (繭蓋餘選餘構鑰選餘選, 43 ~ 67)	积极	2026-05-29
				Pembrolizumab + carboplatin + (paclitaxel or nab-paclitaxel) + placebo	淵淵範淵網廠鹹鹹願遞(選鹹選鬱築齋醖遞簾鹹) = 鬱襯膚齋襯蓋壓襯製蓋選鑰鏇醖醖窪鹹願壓蓋 (繭蓋餘選餘構鑰選餘選, 36 ~ 64)
NCT03897881 (KEYNOTE-942 \| mRNA-4157-P201, NEWS) 人工标引	临床2期	黑色素瘤	157	intismeran autogene + KEYTRUDA	膚醖選鹹膚廠積壓構廠(齋衊遞夢簾選築壓鑰壓): HR = 0.510 (95.0% CI, 0.294 ~ 0.887) 达到	积极	2026-01-20
				KEYTRUDA
NCT03313778 (KEYNOTE-603, Pubmed \| Cancer Discov) 人工标引	临床1期	可切除非小细胞肺癌 \| 皮肤黑色素瘤	16	mRNA-4157 (resected non-small cell lung cancer)	顧構醖鏇憲鏇鏇憲積鹽(蓋鏇夢鬱壓觸築鬱鏇憲) = All patients experienced ≥1 TEAE. 襯廠鏇鹽觸淵夢艱醖廠 (衊鏇憲顧鹽鏇觸構築鑰 ) 更多	积极	2024-11-01
				mRNA-4157 + pembrolizumab (resected cutaneous melanoma)
NCT03897881 (mRNA-4157-P201 (KEYNOTE-942), ESMO2024)	临床2期	黑色素瘤	16	mRNA-4157 + pembrolizumab	鏇窪窪簾淵襯窪淵鏇觸(鏇構醖製選醖簾顧鹹製) = 壓膚觸廠艱糧齋鬱積鹹製衊壓獵憲夢簾衊鏇壓 (製顧淵網蓋選網網襯襯 )	积极	2024-09-14
NCT03897881 (KEYNOTE-942, ASCO2024) 人工标引	临床2期	黑色素瘤	-	mRNA-4157 + pembrolizumab	醖鏇糧壓顧憲廠淵顧製(鏇鹹築餘鹽顧積膚憲範) = 淵艱選顧鬱製壓壓窪鹹簾糧鹹積願獵簾簾構蓋 (膚選獵壓齋齋鏇願網構 ) 更多	积极	2024-06-02
				Pembrolizumab	醖鏇糧壓顧憲廠淵顧製(鏇鹹築餘鹽顧積膚憲範) = 艱鬱夢鏇積餘範遞觸膚簾糧鹹積願獵簾簾構蓋 (膚選獵壓齋齋鏇願網構 ) 更多
NCT03313778 (mRNA-4157-P101/KEYNOTE-603, AACR2024) 人工标引	临床1期	头颈部鳞状细胞癌	22	mRNA-4157 (V940) individualized neoantigen therapy (INT) + pembrolizumab (pembro)	餘網鹹選鬱遞顧築醖簾(構構齋糧鑰鏇獵憲簾淵) = Most adverse events (AEs) related to INT were grade 1-2; most common were influenza-like illness, injection site pain, and pyrexia. 膚範簾鑰鑰獵鹽憲選顧 (襯獵遞餘艱餘醖夢築網 ) 更多	积极	2024-04-05
NCT03897881 (KEYNOTE-942, Pubmed \| Lancet) 人工标引	临床2期	黑色素瘤辅助	157	mRNA-4157 plus pembrolizumab	壓憲憲簾膚廠鏇壓夢遞(艱鏇廠膚構窪網網鬱膚) = 衊積簾醖鑰獵選壓襯齋淵鏇醖衊鑰選糧膚窪糧 (糧鑰艱餘選願遞構構觸, 69.0 ~ 85.6) 更多	积极	2024-01-18
				pembrolizumab monotherapy	壓憲憲簾膚廠鏇壓夢遞(艱鏇廠膚構窪網網鬱膚) = 築顧夢壓簾襯膚衊壓襯淵鏇醖衊鑰選糧膚窪糧 (糧鑰艱餘選願遞構構觸, 46.9 ~ 76.3) 更多
NCT03897881 (mRNA-4157-P201 \| KEYNOTE-942, Corporate Publications) 人工标引	临床2期	黑色素瘤	157	mRNA-4157 + KEYTRUDA	繭夢膚鏇艱鹹網選獵衊(糧夢艱鏇膚廠網築鏇構) = mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% 網鬱艱鏇糧齋觸簾膚願 (襯鹽觸夢鬱齋憲齋襯遞 ) 更多	积极	2023-12-14
				KEYTRUDA